Search - tctmd.com

Displaying 61 - 80 of 339

Sort: Relevancy | Date

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

L.A. McKeown

November 04, 2022

News Conference News VIVA 2022

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

L.A. McKeown

November 03, 2022

News Conference News ESC 2022

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

L.A. McKeown

August 30, 2022

News Daily News

Worse Complications After PVI in Women Highlight Research Gaps

L.A. McKeown

August 16, 2022

News Daily News

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

L.A. McKeown

August 05, 2022

News Daily News

High Lp(a) May Predict Risk of CV and Limb Events in PAD

L.A. McKeown

July 18, 2022

News Daily News

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

L.A. McKeown

June 29, 2022

News Daily News

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

L.A. McKeown

June 01, 2022

News Conference News SCAI 2022

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

L.A. McKeown

May 23, 2022

News Daily News

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

L.A. McKeown

April 15, 2022

News Conference News ACC 2022

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

L.A. McKeown

April 04, 2022

News Daily News

PAD Significantly Ups Morbidity and Mortality in AMICS

L.A. McKeown

March 29, 2022

News Daily News

Routine IVUS in Peripheral Interventions Supported by Small RCT

L.A. McKeown

March 09, 2022

News Daily News

HawkOne Directional Atherectomy System Recalled Due to Risk of Tip Breakage

L.A. McKeown

January 21, 2022

News Opinion Conversations in Cardiology

Conversations in Cardiology: Do You Use Antibiotics in the Cath Lab?

October 12, 2021

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

L.A. McKeown

October 07, 2021

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

L.A. McKeown

October 06, 2021

News Daily News

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

L.A. McKeown

August 10, 2021

News Daily News

PAD Continues to Elude Clinicians, Despite Gains: AHA

L.A. McKeown

August 05, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

Advertisement

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years

DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark

Worse Complications After PVI in Women Highlight Research Gaps

IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document

High Lp(a) May Predict Risk of CV and Limb Events in PAD

Rivaroxaban Offers VTE Protection in Postprocedure PAD Patients

Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy

DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year

MOSAIC: Home Intervention Boosts Walking Time in PAD Patients

Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD

PAD Significantly Ups Morbidity and Mortality in AMICS

Routine IVUS in Peripheral Interventions Supported by Small RCT

HawkOne Directional Atherectomy System Recalled Due to Risk of Tip Breakage

Conversations in Cardiology: Do You Use Antibiotics in the Cath Lab?

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

Rivaroxaban Safe, Effective in Renal Disease: VOYAGER PAD

PAD Continues to Elude Clinicians, Despite Gains: AHA

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content